Gilead offers a glimpse at hard data to back up its $600M investment in Nimbus’ NASH drug
Gilead $GILD paid $600 million in fast cash to Nimbus to acquire rights to its early-stage NASH drug. And today it offered another reason why, while also demonstrating just how speedy this big biotech’s R&D squad can be when they feel like they’re on to something big.
Their drug, GS-0976, an inhibitor of Acetyl-CoA carboxylase, slashed levels of liver fat — the key culprit in NASH — by a median 43% in 10 patients in an open-label proof-of-concept study covering 12 weeks of therapy. There was a median decrease of 29 percent in hepatic DNL.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.